Publications by authors named "Sandra Silberman"

Claim this Profile
P
Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma.
Samuel A Goldlust, Louis B Nabors, Sigmund Hsu, Nimish Mohile, Paul J Duic, Sandra L Silberman

Neurooncol Adv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia.
Peter J P Croucher, Maya Ridinger, Pamela S Becker, Tara L Lin, Sandra L Silberman

Ann Hematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor.
Michael C Heinrich, Christopher L Corless, George D Demetri, Charles D Blanke, Margaret von Mehren, Sandra Silberman

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracycline-induced cardiotoxicity - are we about to clear this hurdle?
Wolfram C M Dempke, Rafal Zielinski, Christina Winkler, Sandra Silberman, Susanne Reuther

Eur J Cancer· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Amer M Zeidan, Maya Ridinger, Tara L Lin, Pamela S Becker, Gary J Schiller, Sandra L Silberman

Clin Cancer Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A role for the androgen receptor in the treatment of male breast cancer.
Jason Zhu, Carter T Davis, Sandra Silberman, Neil Spector, Tian Zhang

Crit Rev Oncol Hematol· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells.
Daniel P Fitzgerald, David L Emerson, Yongzhen Qian, Talha Anwar, David J Liewehr, Sandra Silberman

Mol Cancer Ther· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Michael C Heinrich, Christopher L Corless, George D Demetri, Charles D Blanke, Margaret von Mehren, Sandra Silberman

J Clin Oncol· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of imatinib in patients with small cell lung cancer.
Bruce E Johnson, Thomas Fischer, Berthold Fischer, David Dunlop, Danny Rischin, Sandra Silberman

Clin Cancer Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib: a targeted clinical drug development.
Renaud Capdeville, Sandra Silberman

Semin Hematol· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of malignant gastrointestinal stromal tumours.
Heikki Joensuu, Christopher Fletcher, Sasa Dimitrijevic, Sandra Silberman, Peter Roberts

Lancet Oncol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview of issues related to imatinib therapy of advanced gastrointestinal stromal tumors: a discussion among the experts.
Sandra Silberman, Heikki Joensuu

Eur J Cancer· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib: the first 3 years.
Renaud Capdeville, Sandra Silberman, Sasa Dimitrijevic

Eur J Cancer· September 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Sandra L Silberman

N Engl J Med· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Jane F Apperley, Martine Gardembas, Junia V Melo, Robin Russell-Jones, Barbara J Bain, Sandra Silberman

N Engl J Med· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis